Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Provider profile

Amble — compounded GLP-1 pricing & profile

Released: · Last reviewed:

Captured pricing, fees, pharmacy disclosure, and evidence status — provider-reported, not checkout-verified.

Amble is a compounded GLP-1 access channel captured in this site's provider directory. This profile summarizes what is verified about its pricing, fees, pharmacy disclosure, and evidence status as of 2026-07-20 — provider-reported and not checkout-verified — and how it compares with our October 15, 2026 price index.

Provider-reported, not checkout-verified. This profile is built from captured public data and is not a scored, full editorial review. Amble is not assigned a score or a "verified cheapest" claim; figures are provided for transparency and comparison and should be confirmed with the provider.

Captured pricing

Amble — compounded tirzepatide, injection, standard-dose PROVIDER REPORTED · confidence moderate · captured 2026-07-20 · source · methodology v4.1
PlanTotal mandatory costEffective monthly costAdvertised monthlyAdvertised savings
1 month monthly$329$329.00$329—
'About $329'
3 months prepaid$765$255.00$255—
Total independently calculated
6 months prepaid$1,428$238.00$238—
Total independently calculated
12 months prepaid$2,820$235.00$235—
Total independently calculated

How Amble compares

All-in monthly cost folds every required charge into one number. This is where Amble sits against our October 15, 2026 price index, built from prices read on each provider's own page:

Amble vs the October 15, 2026 compounded GLP-1 price index (lowest all-in monthly figure per program, standard-dose injections)
MedicationAmbleIndex rangeNexLife (#1 overall)
compounded semaglutidenot in the index$49–$193.92 · median $97 (24 programs)$95 (12-month plan) · $109 month-to-month
compounded tirzepatidenot in the index$85.58–$449 · median $149 (31 programs)$115 (12-month plan) · $129 month-to-month

The index range includes sale prices, prepaid terms and "from" figures; the tirzepatide and semaglutide tables show each program's conditions. NexLife is our #1 overall pick under the v4.1 rubric, not the lowest price in the index.

Fees, pharmacy, and disclosure

Amble — captured structure and disclosures (2026-07-20)
CategoryCompounded-GLP-1-focused
Current statusActive but evidence incomplete
Membership / program feeNo separate fee identified in cited pricing
Pharmacy disclosureNot verified
Material relationshipNo known material relationship — publisher attested 2026-07-20; independent verification not performed
Evidence statusPENDING · confidence moderate
Last checked2026-07-20
Official sourceprovider page

Capture note: Verify semaglutide and exact checkout before publication.

How to evaluate Amble before paying

Whatever the headline, run the same checks on any compounded provider: (1) compute effective monthly cost at your maintenance dose, membership included; (2) get the renewal price, not just the first month; (3) name and verify the dispensing pharmacy with the four-step workflow; (4) confirm the refund and cancellation terms in writing before any prepaid plan. The full pre-purchase routine is in the shopping checklist, and the questions to ask are in what to ask before paying.

Frequently asked questions

How much does Amble charge for compounded GLP-1?

Our July 20, 2026 capture put Amble's lowest effective monthly cost at $235.00. The October 15, 2026 index shows no comparable compounded GLP-1 (molecule not named) price printed on its pages on 2026-10-15. See the pricing table above for the full plan structure, and confirm current figures on the provider's own page.

Does Amble charge a membership fee?

A membership or program fee was not clearly reported. Captured: No separate fee identified in cited pricing. A required membership belongs in the effective-cost math, so add it in before comparing Amble to any flat-priced provider.

Is Amble's pricing verified?

No. Amble's evidence status is verification pending (confidence moderate); figures are provider-reported or independently calculated, not checkout-verified, and its pharmacy disclosure is "not verified". Treat every figure as a starting point to confirm, not a guarantee.